Efficacy and safety of eculizumab in patients with treatment-refractory anti-acetylcholine receptor antibody-positive generalised myasthenia gravis previously treated with rituximab

2021 ◽  
Vol 429 ◽  
pp. 118339
Author(s):  
Francesco Patti ◽  
Tahseen Mozaffar ◽  
Marcus Yountz ◽  
Fanny O'Brien ◽  
Zaeem Siddiqi
2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Jung Jin Lee ◽  
Kyung Min Koh ◽  
Ungsoo Samuel Kim

Aim. To estimate the clinical significance of anti-acetylcholine receptor antibody (anti-AChR-Ab) levels in suspected ocular myasthenia gravis.Methods. In total, 144 patients complaining of fluctuating diplopia and ptosis were evaluated for serum levels of anti-acetylcholine receptor antibody and their medical charts were retrospectively reviewed. Subjects were classified into three groups: variable diplopia only, ptosis only, and both variable diplopia and ptosis. We investigated serum anti-AChR-Ab titer levels and performed thyroid autoantibody tests.Results. Patients’ chief complaints were diplopia (N=103), ptosis (N=12), and their concurrence (N=29). Abnormal anti-AChR-Ab was observed in 21 of 144 patients (14.1%). Between the three groups, mean age, number of seropositive patients, and mean anti-AChR-Ab level were not significantly different (P=0.224, 0.073, and 0.062, resp.). Overall, 27.5% of patients had abnormal thyroid autoantibodies.Conclusion. The sensitivity of anti-AChR-Ab was 14.1% in suspected ocular myasthenia gravis and seropositivity in myasthenia gravis patients showed a high correlation with the presence of thyroid autoantibodies.


1981 ◽  
Vol 4 (1) ◽  
pp. 16-25 ◽  
Author(s):  
Tom Mittag ◽  
Tobias Massa ◽  
Peter Kornfeld ◽  
Angelos Papatestas ◽  
Adam Bender ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document